Deal could put FDA reps in China

Share this article:

A deal between the US and China could mean more FDA inspection of manufacturing plants. Regulatory Focus reports that the countries struck a deal Dec. 5 that officials say will mean “a substantial increase in the number of US food and drug inspectors” on site.

The news could mean a new rash of Warning Letters to read up on: RF notes that on-site inspections in India, for example, netted six Warning Letters in 2012, and inspectors also put a dent in businesses including Wockhardt and Fresenius Kabi, after finding problems with their facilities.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.